[
  {
    "company": "monte_rosa",
    "program_name": "NEK7",
    "timeline": {
      "2024": {
        "targets": [],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 9
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-8102",
    "timeline": {
      "2024": {
        "targets": [
          "NEK7"
        ],
        "e3_ligases": [],
        "modalities": [
          "MGD"
        ],
        "claims": [
          "favorable ADME/DMPK properties",
          "induces selective NEK7 degradation",
          "potent NEK7-directed MGD"
        ],
        "safety": [
          "No inhibition of hERG",
          "Oral bioavailability"
        ]
      },
      "2025": {
        "targets": [
          "Caspase-1",
          "IL-1",
          "IL-17",
          "IL-6",
          "NEK7",
          "NLRP3",
          "TNF"
        ],
        "e3_ligases": [
          "CRBN",
          "cereblon"
        ],
        "modalities": [
          "MGD",
          "Molecular Glue Degrader",
          "molecular glue degrader"
        ],
        "claims": [
          "31% reduction of fibrinogen",
          "85% sustained reduction of hsCRP",
          "94% subjects achieved reduction of hsCRP levels to <2 mg/L",
          "Catalytic MOA drives sustained PD effect",
          "Changes in CRP levels in subjects with high CRP",
          "Changes in gout/pseudogout flare pain or osteoarthritic pain",
          "Changes in levels of inflammatory cytokines",
          "Exquisite selectivity enables high therapeutic index",
          "High degradation in immune and blood cells",
          "Highly selective NEK7 degradation",
          "Inhibits IL-1 downstream of NLRP3 inflammasome activation",
          "Inhibits NLRP3 Activation",
          "Inhibits upstream pyroptosis & DAMP/cytokine release",
          "No MGD induced tox findings in 2 GLP tox studies (VAV1, NEK7)",
          "Potent degradation of NEK7",
          "Potential to deplete both membrane receptors and intracellular signaling nodes",
          "Prevents IL-1 release",
          "Prolonged pharmacodynamic effect",
          "Reduces Caspase-1 activation",
          "Reduction in frequency of gout/pseudogout flares",
          "Safety, tolerability, and pharmacokinetics in healthy volunteers",
          "Suppresses cytokine release in ex vivo-stimulated whole blood",
          "durable NEK7 degrader",
          "favorable AE profile",
          "induced rapid and compelling reduction in hsCRP",
          "inhibition of the NLRP3 inflammasome",
          "potent",
          "selective"
        ],
        "safety": [
          ">200-fold exposure margin over projected human efficacious dose in both species",
          "NOAEL was the highest dose tested, 150 mg/kg/day (rat) and 100 mg/kg/day (cyno)",
          "Negative Mini-Ames",
          "No MRT-8102 related clinical signs",
          "No changes in immunophenotyping",
          "No concerns related to CV safety pharmacology (cyno)",
          "No concerns related to hERG",
          "No concerns related to in vitro off-targets",
          "No concerns related to in vivo respiratory or CNS safety pharmacology (rat)",
          "No concerns related to mutagenicity",
          "No concerns related to phototoxicity",
          "No dose dependency",
          "No evidence of increased infection risk",
          "No gross or clinical pathology findings at any dose level",
          "No inhibition (EC50> 30 \u00b5M)",
          "Safety and tolerability",
          "Safety, and tolerability of 28-day dosing",
          "Treatment-emergent AEs were mild to moderate",
          "Well tolerated with favorable safety profile with no SAEs",
          "no SAEs",
          "no adverse safety signals",
          "no severe AEs"
        ]
      },
      "2020": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": [
          "Safety and tolerability of 28 days dosing"
        ]
      },
      "2026": {
        "targets": [
          "NEK7"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "31% reduction of fibrinogen",
          "85% sustained reduction of hsCRP",
          "94% subjects achieved reduction of hsCRP levels to <2 mg/L",
          "~80-90% NEK7 degradation noted in T cells"
        ],
        "safety": [
          "No SAEs",
          "no severe AEs"
        ]
      }
    },
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa AHA 2025 NEK7 Poster.pdf",
        "slide": 1
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 2
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 5
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 6
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 7
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 8
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 9
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 10
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 11
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 12
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 17
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 21
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 22
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 23
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 24
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 28
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 1
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 3
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 19
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 20
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 23
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-2359",
    "timeline": {
      "2024": {
        "targets": [
          "CRBN",
          "GSPT1"
        ],
        "e3_ligases": [],
        "modalities": [
          "molecular glue degrader"
        ],
        "claims": [],
        "safety": []
      },
      "2023": {
        "targets": [
          "CK1a",
          "GAPDH",
          "GSPT1",
          "GSPT2",
          "IKZF1",
          "IKZF3",
          "L-MYC",
          "MYC",
          "N-MYC",
          "SALL4",
          "ZFP91",
          "c-MYC"
        ],
        "e3_ligases": [
          "CRBN",
          "cereblon"
        ],
        "modalities": [
          "MGD",
          "molecular glue degrader",
          "molecular glue degraders"
        ],
        "claims": [
          "1 patient has SD",
          "1 patient with NSCLC and unclear biomarker status remains on therapy for > 7 months with stable disease",
          "2 have experienced a PR (1 confirmed, 1 unconfirmed)",
          "2 patients experienced a PR (1 confirmed, 1 unconfirmed)",
          "6/15 patients were identified as biomarker positive",
          "Best-in-Class",
          "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155",
          "Demonstrate dose dependent PK",
          "Demonstrate significant GSPT1 degradation at safe dose levels in PBMCs and tissue biopsies (60% based on preclinical data)",
          "Dose dependent exposure in line with preclinical PK",
          "Favorable ADME/DMPK profile",
          "Favorable ADMET profile",
          "Highly Optimized and Potent",
          "Highly Selective",
          "Highly Selective Recruiter and Degrader of GSPT1",
          "Highly selective against common neosubstrates of CRBN",
          "Induced selective GSPT1 degradation",
          "Induces Tumor Regressions in N-MYC-driven Xenograft Models",
          "Level of degradation equivalent across all dose levels, suggesting saturated PD response from 0.5 to 2 mg",
          "MRT-2359 completely abrogates protein synthesis only in N-MYC high cell line",
          "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
          "MRT-2359 induces ribosome stalling at stop codon only in N-MYC high cell line",
          "MRT-2359 preferentially impairs protein synthesis in tumor cells with high MYC expression",
          "MYC down modulation",
          "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359",
          "No clinical activity seen in biomarker negative patients",
          "No food effect observed",
          "Oral bioavailable",
          "Oral dosing shows anti-tumor activity and regressions",
          "PD modulation in PBMCs observed across all dose levels; level of degradation (~ 60%) in line with maximal degradation observed in preclinical studies using the same method",
          "Potent and Selective GSPT1 Degrader",
          "Potent inducer of GSPT1-cereblon proximity",
          "Preferential GSPT1 degradation",
          "Preferential antiproliferative activity in N-MYC high cell lines",
          "Preferential inhibition of translation",
          "Resolution of liver metastases (-41% per RECIST 1.1)",
          "Share potential preliminary efficacy signals in biomarker positive patients",
          "Transcriptional modulation of >200 MYC target genes",
          "Unconfirmed PR in NSCLC with SCLC/NE Transformation",
          "clinical activity",
          "early signs of clinical activity",
          "favorable tolerability profile",
          "good oral bioavailability",
          "high selective effect (2.4 U)",
          "highly selective",
          "optimal PD modulation",
          "optimal degradation kinetics",
          "optimal pharmacodynamic modulation",
          "orally bioavailable",
          "preferential activity in MYC-driven cancer cells",
          "rationally designed to be in the ADMET sweet-spot"
        ],
        "safety": [
          "CEREP (Safety panel 44)",
          "CYP DDIs",
          "CYP DDIs (7 isoforms)",
          "Decreased appetite",
          "Diarrhea",
          "Fatigue",
          "Frequent dose interruptions due to bowel obstruction unrelated to MRT-2359",
          "Hypokalemia",
          "Leukopenia",
          "Nausea",
          "Neutropenia",
          "No activity observed in an in vitro panel of 44 safety targets",
          "No observed clinically significant hypocalcemia or hypotension/cytokine release syndrome",
          "Oral bioavailability all species",
          "Rash",
          "Thrombocytopenia",
          "Vomiting",
          "hERG inhibition (patch clamp)",
          "hERG inhibition patch clamp"
        ]
      },
      "2025": {
        "targets": [
          "GSPT1"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "1 PR (confirmed, -57%)",
          "1 PSA response (-90%)",
          "2 SDs"
        ],
        "safety": [
          "Safety assessments initiated",
          "Safety profile has been favorable",
          "Well-tolerated dose level",
          "{\"AE\": \"Anemia\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Diarrhea\", \"G1-2\": 1, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Fatigue\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Hypokalemia\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Leukopenia\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Nausea\", \"G1-2\": 3, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Neutropenia\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Thrombocytopenia\", \"G1-2\": 0, \"G3\": 0, \"G4\": 0}",
          "{\"AE\": \"Vomiting\", \"G1-2\": 1, \"G3\": 0, \"G4\": 0}"
        ]
      },
      "2026": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "100% PSA response",
          "Overall disease control rate (DCR) of 64%"
        ],
        "safety": [
          "mild or moderate manageable GI adverse events",
          "well tolerated"
        ]
      },
      "2022": {
        "targets": [
          "CK1a",
          "GAPDH",
          "GSPT1",
          "GSPT2",
          "IKZF1",
          "IKZF3",
          "MYC",
          "N-MYC",
          "SALL4",
          "ZFP91"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "MGD",
          "Molecular Glue Degrader"
        ],
        "claims": [
          "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output",
          "Downregulates N-MYC",
          "Induces GSPT1 degradation leading to N-MYC protein downregulation",
          "Induces degradation of GSPT1",
          "MRT-2359 doesn\u2019t inhibit hERG",
          "MRT-2359 has favorable ADMET profile",
          "MRT-2359 induces ribosome stalling only in N-MYC high cell line",
          "MRT-2359 is a selective GSPT1-directed MGD",
          "MRT-2359 is neither an inhibitor, nor an inducer of major CYPs",
          "MRT-2359 is orally bioavailable",
          "MRT-2359 rapidly and completely abrogates protein synthesis only in N-MYC high cell line",
          "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359",
          "Oncogene addiction",
          "Orally Bioavailable",
          "Potent",
          "Preferential anti-tumor activity in MYC-driven tumors",
          "Preferential antiproliferative activity in N-MYC high cell lines",
          "Selective",
          "Synthetic lethality"
        ],
        "safety": [
          "CYP DDIs > 30 \u00b5M",
          "CYP2C19 @ 1.5 uM",
          "Caco2 (Efflux Ratio)",
          "EC50 > 30 \u00b5M",
          "hERG (patch clamp)",
          "hERG inhibition patch clamp"
        ]
      }
    },
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 3
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 16
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 17
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 21
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 1
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 7
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 8
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 9
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 10
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 11
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 12
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 13
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 14
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 15
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 16
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 17
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 18
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 19
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 1
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 10
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 12
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 21
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 23
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 31
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 33
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 34
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 36
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 39
      },
      {
        "document": "MRTx_AACR_2024_MRT2359_Prostate.pdf",
        "slide": 1
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 2
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 5
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 6
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 7
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 8
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 9
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 10
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 11
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 12
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 13
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 14
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 15
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 16
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 17
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 18
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 19
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 20
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 23
      },
      {
        "document": "Monte Rosa AACR Poster April 2022.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 16
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 1
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 4
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 5
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 6
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 7
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 8
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 9
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 10
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 11
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 12
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 13
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 14
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 16
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-6160",
    "timeline": {
      "2024": {
        "targets": [
          "VAV1"
        ],
        "e3_ligases": [
          "Cereblon",
          "cereblon"
        ],
        "modalities": [
          "MGD",
          "molecular glue degrader"
        ],
        "claims": [
          "Favorable ADME/DMPK profile",
          "Induces selective VAV1 degradation",
          "MRT-6160 attenuates B cell activation",
          "MRT-6160 attenuates T cell activation",
          "MRT-6160 reduces autoantibody production",
          "MRT-6160 reduces joint inflammation",
          "MRT-6160 reduces serum levels of pro-inflammatory cytokines",
          "Potent and Selective VAV1-directed MGD",
          "inhibits TCR-induced activation",
          "prevents disease progression",
          "reduces colon inflammation",
          "reduces pro-inflammatory cytokine production"
        ],
        "safety": [
          "> 50%",
          "EC50 > 30 \u00b5M",
          "IC50 > 30 \u00b5M"
        ]
      },
      "2025": {
        "targets": [
          "VAV1"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "molecular glue degrader"
        ],
        "claims": [
          "Achieved Dose-Dependent VAV1 Degradation >90% in Peripheral Blood T Cells After Single and Multiple Dose Administration",
          "Attenuated IL-6 production by 60-90% across dose levels following B-cell stimulation",
          "MRT-6160 has oral bioavailability",
          "MRT-6160 inhibits EAE disease progression, severity, and incidence",
          "MRT-6160 inhibits T and B cell activation",
          "MRT-6160 inhibits T and B cell activation and effector functions",
          "MRT-6160 reduces demyelination",
          "MRT-6160 reduces pro-inflammatory cytokine levels",
          "MRT-6160 reduces spinal cord immune cell infiltration",
          "Marked suppression of CD69 upregulation (>90%) in peripheral blood T and B cells following TCR stimulation",
          "Resulted in Sustained Suppression of TCR-mediated CD69 Activation following Single or Multiple Dose Administration",
          "Significantly (up to 99%) inhibited IL-2, IFN-\u03b3 and IL-17A secretion from whole blood derived T cells following ex vivo TCR stimulation",
          "Significantly attenuated CD69 upregulation on T and B cells following TCR stimulation, reflecting functional inhibition",
          "Similar results observed in peripheral blood B cells following BCR stimulation",
          "attenuates T and B cell effector functions",
          "inhibits disease progression",
          "reduces kidney glomerular and interstitial nephritis"
        ],
        "safety": [
          "MRT-6160 was well tolerated with no serious adverse events (SAE)",
          "Observed treatment-emergent adverse events (TEAE) were mild (82%) or moderate (18%) and self-limiting",
          "Overall TEAE frequency was similar between MRT-6160 and placebo",
          "Safety and tolerability",
          "Safety, PK and PD Data from SAD and MAD Healthy Volunteers",
          "TEAE observed in 2 or more subjects treated with MRT-6160: SAD: pain from vessel puncture (2), MAD: cough (2), diarrhea (3), feeling hot (4), headache (5), nasal congestion (2), oropharyngeal pain (3) and pyrexia (2)",
          "early insights into safety"
        ]
      },
      "2026": {
        "targets": [
          "VAV1"
        ],
        "e3_ligases": [],
        "modalities": [
          "molecular glue degrader"
        ],
        "claims": [],
        "safety": []
      },
      "2023": {
        "targets": [
          "VAV1"
        ],
        "e3_ligases": [
          "Cereblon"
        ],
        "modalities": [
          "molecular glue degrader"
        ],
        "claims": [
          "attenuates antigen receptor-mediated activation and effector functions of T- and B-cells",
          "attenuates disease progression in the CIA autoimmune disease model",
          "rapidly degrades Vav1 in vivo"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 17
      },
      {
        "document": "FOCIS_2025_MRT6160_EAE.pdf",
        "slide": 1
      },
      {
        "document": "MRT_EULAR_2024_MRT6160_CIA_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "MRT_ECTRIMS_2025_MRT6160_EAE_FINAL_PDF.pdf",
        "slide": 1
      },
      {
        "document": "MRT_DDW_2024_MRT6160_IBD_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 3
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 4
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 6
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 7
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 15
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 30
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 1
      },
      {
        "document": "MRT_ACR_2023_MRT6160_CIA_FINAL_PDF.pdf",
        "slide": 1
      },
      {
        "document": "MRT_ACR_2025_MRT6160_SjD_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 24
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "GSPT1",
    "timeline": {
      "2021": {
        "targets": [
          "Myc"
        ],
        "e3_ligases": [],
        "modalities": [
          "molecular glue degraders"
        ],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 6
      },
      {
        "document": "European Protein Degradation Congress - September 21, 2021.pdf",
        "slide": 2
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-9643",
    "timeline": {
      "2024": {
        "targets": [
          "CDK2"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "MGD",
          "Molecular Glue Degrader"
        ],
        "claims": [
          "CDK2 degradation achieves equivalent efficacy compared to anti-CDK4/6 and anti-estrogen standard of care",
          "CDK2 degradation delays resistance to CDK4/6 inhibition",
          "CDK2 degradation inhibits CDK2-dependent cancer cell proliferation",
          "Favorable ADME/DMPK profile",
          "Induces Strong Pathway Suppression",
          "Induces highly selective CDK2 degradation",
          "Induces robust pathway suppression in combination with breast cancer SoC",
          "MRT-9643 counteracts resistance to CDK4/6 inhibition in HR-positive cells",
          "MRT-9643 demonstrates activity and pathway suppression in combination with CDK4/6 inhibition",
          "MRT-9643 exhibits potency, selectivity, and favorable drug-like properties",
          "MRT-9643 inhibits proliferation of CDK2-dependent cancer cells",
          "No degradation of other known CRBN neosubstrates",
          "Potent and Highly Selective CDK2-directed MGD",
          "Readily degrades CDK2 in vivo",
          "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
          "induces strong TGI in combination with CDK4/6 inhibitor in vivo",
          "induces strong TGI in combination with CDK4/6 inhibitors in vivo"
        ],
        "safety": [
          "IC50 15 - >50 \u00b5M",
          "hERG inhibition patch clamp"
        ]
      }
    },
    "evidence": [
      {
        "document": "P5-01-26_Ilic-Widlund.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 7
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 13
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "AR H875Y Mutation",
    "timeline": {
      "2025": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Confirmed PR"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 40
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-50969",
    "timeline": {
      "2024": {
        "targets": [
          "Cyclin E1",
          "E2F targets",
          "cyclin E1"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "Molecular Glue Degrader"
        ],
        "claims": [
          "First-in-class cyclin E1 degrader for cyclin E1 amplified cancers",
          "Induction of senescence by cyclin E1 degradation is RB-dependent",
          "Loss of RB blunts growth suppression induced by MRT-50969",
          "MRT-50969 degrades cyclin E1 and inhibits downstream pathway activity in vivo",
          "MRT-50969 induces robust G1/S cell cycle arrest",
          "MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model",
          "MRT-50969 is a potent and highly selective cyclin E1-directed MGD",
          "MRT-50969 is orally bioavailable and shows anti-tumor activity in a dose dependent manner in CCNE1-amplified cell line-derived xenograft models",
          "MRT-50969 shows superior differential activity in CCNE1 dependent cell lines compared to clinical-stage CDK2 inhibitors",
          "degrades cyclin E1",
          "inhibits tumor growth"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 44
      },
      {
        "document": "ENA_2024_CCNE1_poster.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 18
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 19
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 20
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 22
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 24
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 25
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 26
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-51443",
    "timeline": {
      "2025": {
        "targets": [
          "CDK2"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "Molecular Glue Degrader"
        ],
        "claims": [
          "MRT-51443 counteracts resistance to CDK4/6 inhibition in HR+ breast cancer models.",
          "MRT-51443 displays superior selectivity compared to clinical CDK2 inhibitors.",
          "MRT-51443 exhibits favorable PK and PD profiles.",
          "MRT-51443 induces robust tumor regression in combination with CDK4/6 inhibition and Fulvestrant.",
          "MRT-51443 inhibits proliferation of CDK2-dependent cancer cells.",
          "MRT-51443 is a potent and highly selective CDK2-directed molecular glue degrader.",
          "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
          "substantially reduces tumor growth vs. ribo + fulv"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 45
      },
      {
        "document": "Selective Targeting of CDK2 Using Molecular Glue Degraders.pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-048",
    "timeline": {
      "2021": {
        "targets": [
          "GSPT1"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "European Protein Degradation Congress - September 21, 2021.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-474",
    "timeline": {
      "2025": {
        "targets": [
          "IRAK4"
        ],
        "e3_ligases": [],
        "modalities": [
          "Oral QD Small Molecule Degraders",
          "oral degrader"
        ],
        "claims": [
          "Early signs of strong clinical activity",
          "Favorable safety profile",
          "Robust IRAK4 degradation",
          "Systemic suppression of proinflammatory cytokines and chemokines"
        ],
        "safety": [
          "Favorable safety profile"
        ]
      },
      "2021": {
        "targets": [
          "IRAK1",
          "IRAK2",
          "IRAK3",
          "IRAK4",
          "MyD88",
          "TLRs",
          "TRAF6"
        ],
        "e3_ligases": [],
        "modalities": [
          "oral"
        ],
        "claims": [
          "Achieved >98% IRAK4 Degradation",
          "Achieved Near Complete and Sustained IRAK4 Degradation with Multiple Daily Oral Doses (14 Days)",
          "Dose-dependent IRAK4 degradation in skin",
          "IRAK4 knockdown of \u226585% in whole blood achieved anti-inflammatory effect comparable to potent corticosteroids or approved standard of care drugs",
          "KT-474 DC50 = 2.1 nM in human immune cells",
          "KT-474 better able to inhibit IL-6 under both LPS and LPS + IL-1\u03b2 than clinically active IRAK4 SM kinase inhibitor PF-06550833",
          "KT-474 only degraded IRAK4 in human immune cells at concentration 10-fold above the DC90",
          "MAD 2 through 4 approached Lower Limit of Quantitation (LLOQ)",
          "Mean IRAK4 levels at 200 mg dose nearing LLOQ by Day 14, with knockdown up to 90% at 200 mg",
          "Plateau in IRAK4 Reduction after 14 days in PBMC after 100 mg",
          "Recovery towards baseline by Day 28 (2 weeks after last dose)",
          "Reduced IRAK4 to Near LLOQ in the Skin",
          "Steady state IRAK4 reduction achieved between Days 7 and 14",
          "best-in-class",
          "marked reduction of IRAK4 protein in blood and skin",
          "prolonged suppression of IRAK4 in blood and skin",
          "proof of biology (broad inhibition of cytokine induction)",
          "proof of mechanism (IRAK4 degradation)",
          "strong and broad inhibition of whole blood ex vivo cytokine induction"
        ],
        "safety": [
          "Safety & tolerability",
          "shown to be safe and well-tolerated"
        ]
      },
      "2022": {
        "targets": [
          "CRP",
          "IL-1\u03b2",
          "IL-6",
          "IRAK4",
          "SAA"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Associated with up to 85% inhibition of multiple disease-relevant cytokines and chemokines in ex vivo TLR stimulation assay at 100 mg dose",
          "Dose-dependent IRAK4 degradation in skin of >50%",
          "Generally well tolerated at doses up to 200 mg with no SAEs",
          "IRAK4 degradation of 80-90% in PBMC using Flow Cytometry",
          "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range was neither dose- nor exposure-dependent",
          "Reduction to near lower limit of quantification with Mass Spectrometry",
          "demonstrating degrader vs. small molecule inhibitors (SMI) biological differentiation",
          "modest, non-adverse QTcF prolongation observed",
          "potential best in class oral drug",
          "potential best in class profile in I/I",
          "promising clinical activity exceeding benchmark placebo rates",
          "robust degradation of IRAK4 associated with systemic anti-inflammatory effect",
          "safety, PK and PD comparable to healthy volunteers",
          "superior clinical potential over SMI"
        ],
        "safety": [
          "Generally well tolerated at doses up to 200 mg with no SAEs",
          "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range",
          "demonstrated fidelity of translation of PK, PD and safety across three clinical programs in I/I and oncology patients",
          "modest, non-adverse QTcF prolongation observed to spontaneously resolve",
          "safety, PK and PD comparable to healthy volunteers"
        ]
      }
    },
    "evidence": [
      {
        "document": "Kymera R.pdf",
        "slide": 38
      },
      {
        "document": "Kymera R.pdf",
        "slide": 71
      },
      {
        "document": "Kymera R.pdf",
        "slide": 72
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 21
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 24
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 25
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 26
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 28
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 29
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 31
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 34
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 35
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 36
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 37
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 38
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 42
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 95
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 99
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 4
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 23
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 26
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 27
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 32
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 33
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 35
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 36
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 39
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 41
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 50
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 59
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 61
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 62
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-294",
    "timeline": {
      "2025": {
        "targets": [
          "TYK2"
        ],
        "e3_ligases": [],
        "modalities": [
          "oral degrader"
        ],
        "claims": [
          "Mega-blockbuster potential for oral degrader with biologic-like activity that is superior to TYK2 SMI",
          "Potential Best-in-Class Opportunity with Biologic-like Profile"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Kymera R.pdf",
        "slide": 65
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-621",
    "timeline": {
      "2025": {
        "targets": [
          "CCL13/MCP-4",
          "CCL17/TARC",
          "CCL18/PARC",
          "CCL26/Eotaxin-3",
          "CXCL1/GRO-\u237a",
          "IL-13",
          "IL-31",
          "IL-4",
          "KRT16/Keratin 16",
          "MMP12",
          "OSMR/Oncostatin-M receptor",
          "PI3/Peptidase inhibitor 3",
          "POSTN/Periostin",
          "S100A12",
          "STAT6",
          "TSLP"
        ],
        "e3_ligases": [],
        "modalities": [
          "Oral Degrader",
          "Oral Small Molecule Degrader",
          "degrader"
        ],
        "claims": [
          "100% responder rate in ACQ-5",
          "56% median FeNO reduction at Day 29",
          "74% median TARC reduction similar to dupilumab at week 4 when stratifying for patients with similar baseline TARC levels",
          "90% STAT6 degradation leads to comparable or superior in vivo efficacy to dupilumab in asthma models",
          ">90% STAT6 Degradation in Blood Across All Dose Levels",
          ">90% STAT6 degradation in blood in all doses above 1.5 mg",
          ">95% Mean STAT6 Degradation Achieved at Doses of 75 mg or Greater",
          "Achieved 76% Overall Mean Reduction in SCORAD-Sleeplessness",
          "Achieved >90% STAT6 Degradation in Blood at All Dose Levels Above 1.5 mg",
          "Achieved Complete STAT6 Degradation in Skin",
          "Achieved Median Serum Eotaxin-3 Reduction of up to 73%",
          "Achieved Median Serum IgE Reduction of up to 14%",
          "Achieved Median TARC Reduction of 74% in Patients with TARC Levels Comparable to Dupilumab AD Studies",
          "Achieved Robust Clinical Improvement Across EASI-50, EASI-75, and vIGA-AD 0/1 Measures",
          "Achieved Robust and Consistent Reductions in Itch Across Independent Clinical Measures",
          "Achieved mean changes of -0.8 in RQLQ",
          "Achieved mean changes of \u20130.9 in TNSS",
          "Achieved up to 33% Reduction in FeNO in AD Patients",
          "Blocks Th2 Inflammation in Vivo",
          "Clinical activity",
          "Compelling Clinical Profile",
          "Compelling Preclinical Profile",
          "Complete Degradation Achieved at Doses of 50 mg or Greater",
          "Complete STAT6 Degradation in Blood",
          "Complete STAT6 degradation achieved at doses \u22655 mg",
          "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
          "Complete STAT6 degradation selectivity in human PBMC at 100xDC90",
          "Deep STAT6 Degradation in Blood and Skin",
          "Deep STAT6 degradation in blood and skin",
          "Deep degradation maintained throughout dosing period",
          "Deep skin degradation with multiple patients\u2019 STAT6 levels below the LLOQ",
          "Degrades STAT6 at Low Oral Doses in All Relevant Tissues",
          "Demonstrate that KT-621 has a dupilumab-like biomarker signature in blood and skin lesions",
          "Dose Responsive STAT6 Degradation in Dog Blood",
          "Dupi-like profile",
          "Dupilumab-like Activity in a Pill",
          "Dupilumab-like activity",
          "Dupilumab-like impact on EASI, SCORAD and multiple measures of pruritus",
          "Dupilumab-like reductions in TARC, Eotaxin-3 and IgE",
          "Dupilumab-like reductions in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions",
          "Early evidence of activity in asthma and allergic rhinitis",
          "Efficacy and safety in two initial Th2 diseases",
          "Excellent Preclinical Activity Comparable or Superior to Dupilumab",
          "Exquisite Selectivity",
          "First known demonstration of FeNO reduction in AD patients",
          "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
          "Full inhibition of IL-4/IL-13 pathways more potent than dupilumab",
          "Fully Blocks IL-4/13 Pathway",
          "IC50\u2019s Lower than Dupilumab",
          "IL-4/IL-13 Pathway Inhibition",
          "IgE reduction comparable to dupilumab data in AD studies at week 41",
          "KT-621 reached dupilumab-like TARC inhibition",
          "KT-621 was well-tolerated with a safety profile undifferentiated from placebo",
          "Maximal degradation seen as quickly as 4 hours after single dose",
          "Mean % Change from Baseline at D29 Overall: -40%",
          "Mean % Change from Baseline at D29 for KT-621 100 mg QD: -47%",
          "Mean % Change from Baseline at D29 for KT-621 200 mg QD: -35%",
          "Meaningful improvements of clinical endpoints and patient-reported outcomes",
          "Median STAT6 degradation of 94% in skin in both dose groups after 4 weeks of treatment using targeted Mass Spec",
          "Median STAT6 degradation of 98% in blood in both dose groups after 4 weeks of treatment",
          "Most subjects with STAT6 levels below LLOQ at doses of \u22655 mg",
          "Multiple subjects with STAT6 levels below LLOQ at doses of 75 mg or greater",
          "No rescue therapy required during treatment period",
          "Only STAT6 Degradation Has the Potential to Lead to Dupilumab-Like Pathway Inhibition",
          "Only STAT6 degradation has the potential to fully block IL-4/IL-13 signaling with an oral daily drug",
          "Ph3 dose selection for clinical activity franchise",
          "Plasma PK profile at 100 and 200 mg similar to healthy volunteer study",
          "Potential for Dupilumab-like Activity",
          "RQLQ responder rate was 33%",
          "Rapid and robust mean Peak Pruritus NRS and SCORAD-Itch reduction in both dose cohorts",
          "Rapid and robust mean SCORAD-Sleeplessness reduction in both dose cohorts",
          "Rapid and robust reduction of TARC across both dose cohorts",
          "Reduction exceeds the dupilumab 52-week results of 51% median reduction in CRSwNP trial and 38% in asthma trial",
          "Reduction of IL-31",
          "Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
          "Robust Degradation in Relevant Cell Types",
          "Robust STAT6 Degradation",
          "Robust STAT6 degradation observed at first time point measured (8hr) for all doses above 1.5 mg",
          "Robust degradation maintained as long as 4 days after single dose with recovery by Day 14",
          "Robust inhibition of several biomarkers, comparable/superior to published dupilumab data",
          "Robust reduction of pruritogenic cytokine IL-31",
          "Robust reductions in Type 2 biomarkers in blood, skin lesions and lung (FeNO)",
          "STAT6 Degradation in All Relevant Tissues in NHP",
          "Safety & tolerability",
          "Safety and tolerability",
          "Similar effect in patients with low or high baseline EASI/TARC",
          "Single doses of KT-621 achieved rapid, deep and prolonged STAT6 degradation in blood",
          "Steady-state maximum degradation achieved as early as 8hr post-first dose with recovery starting at 4 days post-last dose",
          "Strong fidelity of translation from Phase 1a healthy volunteer study to AD patients",
          "Strong translation from healthy volunteer study",
          "TNSS responder rate was 57%",
          "Well-tolerated in preclinical studies",
          "blocked IL-4/13 biomarkers equally or numerically better than dupilumab",
          "demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
          "disrupt a biologics-dominated market",
          "improvements on FeNO in AD and comorbid asthma patients",
          "improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
          "oral, biologics-like profile",
          "potential to broaden clinical access",
          "results in line with or in some cases numerically exceeded published data for dupilumab at week 4",
          "robustly degrade STAT6 in blood and skin at doses that are safe and well-tolerated",
          "safely and deeply degraded STAT6",
          "\u226595% mean STAT6 degradation at doses \u22655 mg"
        ],
        "safety": [
          "Dosing for 28 days",
          "Favorable safety profile",
          "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing",
          "No SAEs",
          "No Severe AEs",
          "No TRAEs >1 subject",
          "No adverse safety findings in any doses of 4-week GLP tox studies in NHP and rodents",
          "No clinically relevant changes in vital signs, laboratory tests, and ECGs",
          "No dose dependent pattern in the TEAEs",
          "No related TEAEs leading to discontinuation",
          "No treatment related AE reported in >1 participant",
          "Safety & tolerability of escalating single and multiple doses of KT-621",
          "Safety profile similar to Phase 1a healthy volunteer trial",
          "Safety profile undifferentiated from placebo",
          "Safety, PK, STAT6 degradation, Th2 biomarkers in blood and skin lesions, clinical activity (EASI, pruritus, IGA)",
          "Well Tolerated Across All Doses Evaluated Undifferentiated from Placebo",
          "Well tolerated",
          "Well tolerated at 90%+ degradation",
          "Well tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose",
          "Well-tolerated",
          "Well-tolerated across all dose levels",
          "Well-tolerated and favorable safety profile similar to Phase 1a healthy volunteer study",
          "Well-tolerated in multiple preclinical safety studies at >40x efficacious concentration",
          "safely and deeply degraded STAT6"
        ]
      },
      "2026": {
        "targets": [
          "CCL13/MCP-4",
          "CCL17/TARC",
          "CCL18/PARC",
          "CCL26/Eotaxin-3",
          "IL-13",
          "IL-4",
          "STAT6"
        ],
        "e3_ligases": [],
        "modalities": [
          "oral"
        ],
        "claims": [
          "100% responder rate in ACQ-5",
          "56% median FeNO reduction at Day 29",
          "Achieved Deep STAT6 Degradation in Blood and Skin",
          "Achieved Rapid and Robust Reductions in EASI and SCORAD Across All Patients",
          "Achieved mean changes of -0.8 points in RQLQ",
          "Achieved mean changes of \u20130.9 points in TNSS",
          "Achieved robust clinical improvement across EASI-50 (76% overall), EASI-75 (29% overall) and vIGA-AD (19% overall)",
          "Blocked IL-4 and IL-13 signaling in human cells and in vivo systems equally or more potently than dupilumab",
          "Blocks Type 2 inflammation in lungs (FeNO) and relieves asthma symptoms (ACQ-5)",
          "Blocks Type 2 inflammation in skin and impacts AD lesions (EASI, vIGA-AD, and skin transcriptomic changes)",
          "Compelling Clinical Profile",
          "Compelling Preclinical Profile",
          "Deep STAT6 degradation",
          "Deep STAT6 degradation >94/95% in HV & patients with AD in skin",
          "Deep STAT6 degradation >95% in HV & patients with AD in blood",
          "Deep STAT6 degradation in blood and skin",
          "Deep skin degradation of 94% in both dose groups with multiple patients\u2019 STAT6 levels below the LLOQ",
          "Degradation Maintained for 28 Days Across Both Dose Cohorts",
          "Dupilumab-like activity",
          "Excellent Preclinical Activity Comparable or Superior to Dupilumab",
          "Exquisite Selectivity",
          "Favorable safety profile",
          "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
          "Meaningful improvements of clinical endpoints and patient-reported outcomes",
          "Meaningful improvements on clinical endpoints and PROs",
          "Median STAT6 degradation of 98% in blood in both dose groups maintained throughout the treatment period",
          "Potential for Dupilumab-like Activity",
          "Potential for Dupilumab-like Activity in a Pill",
          "RQLQ responder rate was 33%",
          "Reductions in Multiple Disease-Relevant Type 2 Biomarkers",
          "Reductions seen as early as Day 8 without apparent plateau during treatment duration",
          "Relieves allergic rhinitis symptoms (TNSS, RQLQ)",
          "Robust Degradation in Relevant Cell Types",
          "Robust STAT6 Degradation in Blood and Skin Following Low Daily Oral Doses",
          "Robust activity in asthma and AD in mouse models",
          "Robust and consistent reductions in itch (PPNRS, SCORAD Itch, IL-31)",
          "Robust reductions in Type 2 biomarkers",
          "TNSS responder rate was 57%",
          "blocked IL-4/13 biomarkers equally or numerically better than dupilumab",
          "demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
          "has the potential to offer 'what patients want'",
          "improvements on FeNO in AD and comorbid asthma patients",
          "improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
          "results in line with or in some cases numerically exceeded published data for dupilumab at week 4",
          "safely and deeply degraded STAT6",
          "transforming the treatment of AD, asthma, and other Type 2 diseases"
        ],
        "safety": [
          "4 months rat and NHP GLP tox",
          "Embryofetal development tox in rat, rabbit and NHP",
          "Favorable safety profile",
          "Favorable safety profile: well-tolerated across all dose levels with safety profile undifferentiated from placebo",
          "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing",
          "No AEs at any doses in: 4 weeks rat and NHP GLP tox",
          "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
          "No SAEs or Severe AEs",
          "No Serious Adverse Events",
          "No Severe Adverse Events",
          "No Treatment Related AE (TRAE) reported in >1 participant",
          "No clinically relevant changes in vital signs, laboratory tests or ECGs",
          "No clinically relevant changes in vital signs, laboratory tests, and ECGs",
          "No dose dependent pattern in Treatment Emergent Adverse Events (TEAEs)",
          "No dose-dependent pattern in the TEAEs",
          "No related TEAEs leading to discontinuation",
          "No related TEAEs or TEAEs leading to discontinuation",
          "Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo",
          "Well-tolerated and favorable safety profile",
          "Well-tolerated with favorable safety at both 100 mg and 200 mg",
          "no side effects or safety issues",
          "safely"
        ]
      }
    },
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 20
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 21
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 24
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 13
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 14
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 19
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 20
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 30
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 31
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 32
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 33
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 53
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 56
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 57
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 58
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 60
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 1
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 3
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 9
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 11
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 12
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 13
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 14
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 15
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 30
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 31
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 32
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 33
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 38
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 39
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 40
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 41
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 42
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 43
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 44
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 45
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 46
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 47
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 48
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 49
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 50
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 53
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 55
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 56
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 1
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 2
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 12
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 13
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 15
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 19
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 21
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 24
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 26
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 33
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 37
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-6",
    "timeline": {
      "2025": {
        "targets": [
          "STAT6"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Complete STAT6 Degradation Selectivity in Human PBMC Proteosome at 100 x DC90",
          "Excellent Degradation Potency and Selectivity",
          "Picomolar Potency and Consistent Degradation Across all Disease-Relevant Cell Types Evaluated"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 19
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-579",
    "timeline": {
      "2025": {
        "targets": [
          "Autoantibodies",
          "IFN\u03b2",
          "IFR5",
          "IL-12p40",
          "IL-1\u03b2",
          "IL-6",
          "IRF5",
          "TNF\u03b1",
          "Type-I IFN",
          "pro-inflammatory cytokines"
        ],
        "e3_ligases": [],
        "modalities": [
          "Oral Degrader",
          "oral degrader"
        ],
        "claims": [
          "Degradation and selectivity",
          "Degrades all Cytoplasmic and Nuclear IRF5 (but not IRF3/7)",
          "Demonstrated Generally Better Outcomes than Approved or Clinically Active Drugs",
          "Effectively Blocks Circulating Cytokines In Mouse Model",
          "Excellent safety profile",
          "Inhibition of pro-inflammatory cytokines",
          "Inhibits IgG Levels After TLR9 Activation (CpG-B)",
          "Inhibits IgG production in SLE derived B cells",
          "KT-579 blocks Type I IFN dependent genes at least as effectively as an anti-TLR7/8 drug (Afimetoran)",
          "KT-579 inhibits TLR7/8 induced ISGs that are associated with increased disease activity in SLE",
          "Leads to Significant Dose-dependent Inhibition of TLR7-R848 and TLR9-CpG-B Cytokine Production in Mouse",
          "No adverse effects at up to 200-fold predicted human efficacious exposure",
          "Potently degrades IRF5",
          "Prevented disease associated mortality better than all other approved or clinically active agents tested",
          "Reduced proteinuria",
          "Reduces Joint Swelling",
          "Reduces TLR9 (CpG-B) induced plasmablast differentiation",
          "Selectively depletes TLR7/8 induced IRF5 nuclear translocation, while sparing IRF7 and IRF3",
          "Significant Reduction in Circulating Pro-inflammatory Cytokines",
          "Type-I IFN inhibition",
          "best-in-class profile",
          "first-in-class",
          "highly selective",
          "potent",
          "selective",
          "well-tolerated"
        ],
        "safety": [
          "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects",
          "favorable safety profile",
          "no AEs in non-GLP tox studies",
          "well-tolerated in safety studies up to 200-fold above the predicted human efficacious concentration"
        ]
      },
      "2026": {
        "targets": [
          "IFR5",
          "IRF5",
          "TLR7",
          "TLR8",
          "TLR9"
        ],
        "e3_ligases": [],
        "modalities": [
          "oral small molecule"
        ],
        "claims": [
          "All KT-579 Treated Mice Survived Length of Study",
          "Clear reduction in IgG/complement glomeruli staining indicating reduced kidney disease involvement in SLE MRL/lpr mouse model with IRF5 degrader as compared to standard of care",
          "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects at up to 200-fold predicted human efficacious exposure",
          "Effectively Blocks TLR Induced Pro-inflammatory Cytokines",
          "KT-579 administered once daily for 63 days was well tolerated and prevented mortality more effectively than all other approved or clinically active comparator agents tested",
          "KT-579 led to sustained reduction of serum anti-dsDNA levels and reduction in splenic plasmablasts, differentiated B cells, and plasma cells, achieving effects comparable to, or better than, standard of care",
          "Leads to Significant Reduction in Joint Swelling Comparable to Tofacitinib",
          "Potently degrades IRF5 across multiple preclinical species with low oral doses",
          "Reduces Joint Swelling",
          "Reduces Total IgG levels in SLE PBMC Samples",
          "Results in significant reduction of circulating pro-inflammatory cytokines",
          "Results in significant reduction of pathogenic infiltrating T cells",
          "Significantly Decreases IgG, Complement 3 (C3) and Renal Disease Progression",
          "Sustained Reduction of Serum Anti-dsDNA",
          "favorable safety profile",
          "first-in-class",
          "fully degrades IRF5",
          "potent",
          "selective"
        ],
        "safety": [
          "Excellent safety profile",
          "de-risk safety"
        ]
      }
    },
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 26
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 37
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 38
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 39
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 40
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 41
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 42
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 43
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 44
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 45
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 47
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 48
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 49
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 37
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 42
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 43
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 44
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 45
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 46
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 48
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 49
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "IRF5 Degrader",
    "timeline": {
      "2025": {
        "targets": [
          "IRF5"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Decreased Proteinuria",
          "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
          "Superior Activity Reducing Anti-dsDNA at Week 37"
        ],
        "safety": []
      },
      "2026": {
        "targets": [
          "IRF5"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Decreased Proteinuria",
          "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
          "Superior Activity Reducing Anti-dsDNA at Week 37"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 46
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 47
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-485",
    "timeline": {
      "2026": {
        "targets": [
          "IRAK4"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "highly selective",
          "oral",
          "potent"
        ],
        "safety": [
          "absence of any QTc signal"
        ]
      }
    },
    "evidence": [
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 51
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 64
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "SAR444656",
    "timeline": {
      "2021": {
        "targets": [
          "IRAK4"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 46
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-413",
    "timeline": {
      "2021": {
        "targets": [
          "Aiolos",
          "IRAK1",
          "IRAK4",
          "Ikaros"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "Complete or partial regressions",
          "Extended tumor exposure",
          "First US Approval (Accelerated)",
          "Highly Active on Intermittent Dosing Regimens",
          "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with Rituxan",
          "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax",
          "KT-413 administered on intermittent schedules leads to strong regressions in combination with the BTK inhibitor Ibrutinib",
          "More active in MYD88MT DLBCL cells than CC-220 and KTX-545",
          "Potent Degrader of IRAK4 and IMiD Substrates",
          "Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population",
          "Profound antitumor effect in vitro and in vivo",
          "Second US Approval (Full)",
          "Strong degradation of both IRAK4 and IMiD substrates",
          "Superior Anti-tumor activity"
        ],
        "safety": [
          "MTD/RP2D",
          "safety",
          "tolerability"
        ]
      },
      "2022": {
        "targets": [
          "Aiolos",
          "IRAK4",
          "Ikaros"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "40% KD of IRAK4 in blood",
          "At least 72h target degradation observed",
          "Complete Tumor Regressions",
          "PD Effects of KT-413",
          "PK Parameters of KT-413",
          "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
          "Preliminary Estimates of Activity",
          "Safety/Tolerability and MTD and RP2D",
          "Safety/Tolerability at RP2D in Patients with DLBCL",
          "Strong antitumor activity",
          "Superior activity compared to IMiD CC-220",
          "Up to 95/100% KD of Ikaros/Aiolos"
        ],
        "safety": [
          "First 2 dose levels generally well-tolerated",
          "No DLTs",
          "No neutropenia observed",
          "No treatment-related SAEs"
        ]
      }
    },
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 49
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 52
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 53
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 54
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 55
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 56
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 57
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 17
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 18
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 22
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "IRAKIMiD",
    "timeline": {},
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 51
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-333",
    "timeline": {
      "2021": {
        "targets": [
          "STAT3"
        ],
        "e3_ligases": [],
        "modalities": [
          "heterobifunctional degrader"
        ],
        "claims": [
          "Accelerated Approval",
          "First-in-class Opportunity",
          "Full Approval",
          "Highly Selective Degradation of STAT3",
          "Profound single agent activity",
          "Promising combo activity with anti-PD1",
          "Selective degradation of only STAT3 protein"
        ],
        "safety": [
          "Safety",
          "Tolerability"
        ]
      },
      "2022": {
        "targets": [
          "STAT3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "10 mg/kg sufficient to drive full tumor regression in SU-DHL-1 that was durable for multiple weeks after the last dose",
          "At least 48h of target degradation observed",
          "Complete Tumor Regressions Associated with Robust STAT3 KD for \u223c48h in Preclinical Models",
          "Initial Proof-of-Mechanism demonstrated",
          "No dose-limiting toxicities observed to date",
          "PD Effects of KT-333",
          "PK Parameters of KT-333",
          "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
          "Preliminary Estimates of Activity",
          "STAT3 degradation consistent with preclinical predictions",
          "Safety/Tolerability and MTD and RP2D",
          "Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors",
          "demonstrating PK/PD consistent with pre-clinical models"
        ],
        "safety": [
          "DL1 level generally well-tolerated with no DLTs or treatment-related SAEs"
        ]
      }
    },
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 58
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 61
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 64
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 65
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 66
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 6
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 7
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 8
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 9
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 10
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 13
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 14
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KTX-201",
    "timeline": {
      "2021": {
        "targets": [
          "STAT3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "combination extends survival",
          "complete responders reject tumor rechallenge demonstrating development of long-term immune memory",
          "synergizes with anti-PD-1 leading to 60% complete responses"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 63
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-253",
    "timeline": {
      "2021": {
        "targets": [
          "MDM2",
          "PUMA",
          "p21",
          "p53"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "4 hr target coverage by KT-253 is sufficient to induce apoptosis",
          ">200-fold more potent in tumor cell killing assays than SMI's due to its mechanism of action",
          "Best-in-Class p53 Stabilizer",
          "Blocks the feedback loop which up-regulates MDM2 production",
          "Ensures high activity and improved therapeutic index vs SMI\u2019s",
          "Induces apoptosis in cell lines and in vivo xenografts",
          "Inhibits tumor cell growth with picomolar potency",
          "Intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index",
          "MDM2 Degradation (KT-253, 1 mg/kg) Leads to Fast Increase in p53, p21, and PUMA (Key Apoptotic Biomarker)",
          "More than 200-fold more potent than clinically active MDM2 small molecule inhibitors",
          "Potent MDM2 Degrader",
          "Potent MDM2 degrader",
          "Selective degradation of KT-253",
          "Single Dose of KT-253 Achieves Sustained Tumor Regression",
          "Single Dose of KT-253 Leads to Sustained Tumor Regression",
          "Strongly stabilizes p53",
          "Superior to MDM2/p53 Small Molecule Inhibitors",
          "Superior tumor cell killing (pM range)"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 75
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 78
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 79
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 80
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 81
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 84
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "IRAKIMiD (KT-413)",
    "timeline": {},
    "evidence": [
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "PF-06550833",
    "timeline": {
      "2022": {
        "targets": [
          "IRAK4"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 25
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Cemsidomide",
    "timeline": {
      "2024": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "25% CR rates",
          "44% ORR",
          "best-in-class IKZF1/3 degrader",
          "compelling anti-lymphoma activity",
          "demonstrated monotherapy anti-myeloma and immunomodulatory effects",
          "differentiated PK profile",
          "differentiated safety profile",
          "immunomodulatory effects",
          "potent anti-myeloma activity",
          "potentially best-in-class profile",
          "rapid and potent degradation of IKZF1/3",
          "well tolerated",
          "wide therapeutic index"
        ],
        "safety": [
          "2 DLTs at 100 \u00b5g (grade 4 thrombocytopenia)",
          "low rates of infections and febrile neutropenia",
          "manageable grade 3/4 neutropenia cases",
          "well-tolerated with manageable neutropenia",
          "wide therapeutic index"
        ]
      },
      "2026": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Accelerated Approval",
          "Full Approval"
        ],
        "safety": [
          "Characterize safety and tolerability"
        ]
      },
      "2025": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "34% ORR across all dose levels",
          "50% ORR at highest dose",
          "Achieves >50% degradation of IKZF1",
          "Achieves >80% degradation of IKZF3",
          "Class-leading anti-myeloma activity with 50% ORR",
          "Differentiated safety & tolerability profile",
          "Dose proportional exposure",
          "MRD negativity achieved in 1 patient with a CR at the highest dose level of cemsidomide (100\u00b5g)",
          "Median DOR of 9.3 months",
          "ORR (\u2265 PR) of 34% (23/67) was achieved across all dose levels with a clinical benefit rate (\u2265 MR) of 49%",
          "ORR at the highest dose level of cemsidomide 100\u00b5g was 50% with a clinical benefit rate of 64%",
          "Potential for accelerated approval",
          "Potential to be best-in-class",
          "durable anti-myeloma activity",
          "well tolerated"
        ],
        "safety": [
          "1 DLT at 62.5 \u00b5g QD due to Grade 4 neutropenia lasting >7 days",
          "3 DLTs at 100 \u00b5g QD",
          "5 DLT events at 100 \u00b5g QD (G4 neutropenia, G3 pneumonia in 2 patients, G3 ALT increase, G3 febrile neutropenia)",
          "Differentiated safety & tolerability profile",
          "manageable TEAEs",
          "minimal treatment discontinuations or reductions"
        ]
      }
    },
    "evidence": [
      {
        "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
        "slide": 9
      },
      {
        "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
        "slide": 11
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 8
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 16
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 6
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 9
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 13
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 15
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 27
      },
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 12
      },
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 14
      },
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 16
      },
      {
        "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
        "slide": 6
      },
      {
        "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
        "slide": 19
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 8
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 21
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "cemsidomide",
    "timeline": {
      "2030": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "compelling anti-tumor activity across a range of dose levels",
          "potential backbone therapy",
          "potentially be a best-in-class therapy",
          "well-tolerated with a compelling safety profile"
        ],
        "safety": [
          "compelling safety profile",
          "well-tolerated"
        ]
      },
      "2026": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "36% ORR across all doses evaluated",
          "40% ORR at the second highest dose level (75 \u00b5g)",
          "53% ORR at the highest dose level (100 \u00b5g)",
          "Cemsidomide has potential for multibillion dollar opportunities across multiple lines of therapy",
          "Cemsidomide has the potential to capture a valuable portion of the large global multiple myeloma market",
          "Combination is safe",
          "Compelling anti-myeloma activity",
          "Differentiated safety profile",
          "Early evidence of anti-myeloma activity",
          "Estimated peak revenue for initial cemsidomide opportunity is $2.5-$4B",
          "Minimal disruptive adverse events",
          "No discontinuations related to cemsidomide",
          "Potential Best-in-Class Next-generation IKZF1/3 Degrader",
          "Potential best-in-class profile",
          "T-cell activation observed across all cemsidomide dose levels",
          "best-in-class profile",
          "de-risked development plan with two distinct opportunities for accelerated approval",
          "differentiated safety & tolerability profile with class-leading anti-myeloma activity",
          "potential best-in-class profile",
          "potential path to AA"
        ],
        "safety": [
          "Differentiated safety & tolerability profile",
          "Differentiated safety profile",
          "Grade 3/4 neutropenia: 59%",
          "No dose discontinuations related to cemsidomide",
          "Only 6% dose reductions due to TEAEs"
        ]
      },
      "2025": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "Very good partial response",
          "class-leading efficacy",
          "differentiated safety & tolerability profile"
        ],
        "safety": [
          "Characterize the safety and tolerability of cemsidomide in combination with elranatamab"
        ]
      },
      "2024": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
        "slide": 34
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 4
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 12
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 13
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 15
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 19
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 31
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 3
      },
      {
        "document": "October 8K Deck_10.15.2025_FINAL.pdf",
        "slide": 28
      },
      {
        "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
        "slide": 29
      },
      {
        "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
        "slide": 38
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 9
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT1946",
    "timeline": {
      "2023": {
        "targets": [
          "BRAF V600",
          "BRAF-V600E",
          "BRAF-V600X",
          "Mutant BRAF",
          "NRAS-Q61K"
        ],
        "e3_ligases": [
          "CRBN",
          "cereblon"
        ],
        "modalities": [
          "BiDAC",
          "BiDACTM degrader",
          "BiDAC\u2122 degrader",
          "Degrader"
        ],
        "claims": [
          "Active in BRAF-V600E/NRAS-Q61K, a model of clinical resistance to BRAF inhibitors",
          "Address failures in inhibitor-based therapy due to resistance mechanisms",
          "Avoid paradoxical activation of RAF dimers",
          "CFT1946 Degrades BRAF-V600E in a Dose Dependent Manner",
          "CFT1946 as a single agent and in combination with MEKi is effective in MAPK pathway inhibition, superior to BRAFi",
          "Causes BRAF-V600E Degradation",
          "Combination treatment of BRAFi resistant xenograft model with CFT1946 and MEKi shows tumor growth inhibition/regression",
          "Effect deep elimination of mutant BRAF signaling and create durable responses",
          "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
          "Loss of Viability in BRAF-V600E Cells",
          "Potent Inhibition of MAPK Signaling",
          "Prevent mutant BRAF-V600X incorporation into RAF dimers",
          "Specifically target mutant BRAF-V600X over wildtype BRAF",
          "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition",
          "potent and mutant-selective",
          "superior to inhibitors in in vitro and in vivo models"
        ],
        "safety": []
      },
      "2022": {
        "targets": [
          "BRAF-V600E",
          "BRAF-V600X",
          "Mutant BRAF",
          "NRAS-Q61K",
          "mBRAF"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "BiDAC",
          "BiDACTM degrader",
          "Selective Degrader",
          "targeted protein degradation"
        ],
        "claims": [
          "CFT1946 degrades BRAF-V600E in a dose dependent manner",
          "CFT1946 provides proof of concept for degradation of selected non-V600E mBRAF of both Class II and Class III",
          "CFT1946 treatment demonstrates degradation of HA-tagged mBRAF in a dose-dependent manner",
          "CFT1946 treatment of Class III mBRAF model cell line shows proof of concept for TPD-mediated growth inhibition superior to BRAFi",
          "CFT1946 treatment of H1666 cells shows modest growth inhibition, superior to inhibition alone",
          "Causes BRAF-V600E Degradation",
          "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
          "Loss of Viability in BRAF-V600E Cells",
          "Potent Inhibition of MAPK Signaling",
          "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition"
        ],
        "safety": []
      },
      "2024": {
        "targets": [
          "APC",
          "BRAF",
          "BRAF V600",
          "BRAF V600 Mutants",
          "BRAF V600E",
          "BRAF V600X",
          "BRAF-V600E",
          "MEK1",
          "MEK2",
          "NRAS",
          "RNF43",
          "TERT",
          "TP53"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "BiDAC degrader",
          "degrader",
          "targeted protein degradation"
        ],
        "claims": [
          "8/11 melanoma patients demonstrated tumor reduction",
          "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
          "Anti-tumor activity seen across multiple BRAF V600 mutants",
          "Assess PK and PD",
          "Avoids paradoxical activation seen with approved inhibitors",
          "CFT1946 degrades BRAF V600E protein in all post-treatment biopsies to date",
          "Confirmed Partial Response",
          "Confirmed Partial Response in BRAF V600E Pancreatic Cancer",
          "Decrease in BRAF V600E allele fraction measured in ctDNA using WES",
          "Degradation of mutant BRAF protein overcomes resistance mechanisms",
          "Degraded BRAF V600E protein in all available post-treatment biopsies",
          "Determine RP2D/MTD",
          "Dose-dependent bioavailability",
          "Early Evidence of Anti-Tumor Activity",
          "Early evidence of monotherapy anti-tumor activity",
          "Early evidence of monotherapy anti-tumor activity in patients who progressed after treatment with BRAF inhibitors",
          "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect",
          "Estimate anti-tumor activity",
          "Increased drug exposure observed with dose escalation",
          "Intrinsic resistance in CRC patients supports CFT1946 in combination with cetuximab",
          "Monotherapy anti-tumor activity in patients refractory to BRAF inhibitors",
          "No Grade \u2265 3 cutaneous adverse events commonly seen with wild-type BRAF inhibition",
          "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
          "Potential to disrupt the treatment landscape and become an important option for patients",
          "Potentially deeper and more durable responses than BRAF inhibitors",
          "Prevents BRAF V600 mutant mono/heterodimer formation",
          "Proof of Degrader Concept",
          "Proof of Mechanism",
          "Safety and tolerability",
          "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
          "Specifically targets BRAF V600 mutations, which includes BRAF V600 mutations beyond BRAF V600E",
          "Tumor reduction in 16/27 patients",
          "Tumor reductions observed in patients with various V600 mutation types",
          "Well tolerated and highly selective degrader",
          "Well tolerated safety profile in an advanced and metastatic patient population",
          "abrogates resistance and paradoxical activation associated with RAF dimerization",
          "demonstrates efficacy in multiple models of BRAF V600X-driven cancers",
          "superior activity to clinically approved BRAF inhibitors"
        ],
        "safety": [
          "Likely avoiding AEs associated with inhibition of wild-type BRAF",
          "No Grade \u2265 3 cutaneous adverse events",
          "likely avoiding AEs associated with inhibition of wild-type BRAF"
        ]
      }
    },
    "evidence": [
      {
        "document": "C4_356a_ASCO_2023_Trial_in_progress_poster.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 5
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 6
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 7
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 8
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 9
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 10
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 11
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 3
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 5
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 6
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 7
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 8
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 9
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 14
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 16
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 18
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 19
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 20
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 21
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 3
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 8
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 10
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 11
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 18
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 20
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 21
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 23
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 10
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 13
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 4
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 9
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 11
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 12
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 13
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 14
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 15
      },
      {
        "document": "C4_2024_AACR_CFT1946 _FINAL.pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT7455",
    "timeline": {
      "2022": {
        "targets": [
          "CRBN",
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "CRBN",
          "cereblon"
        ],
        "modalities": [
          "MonoDAC Degrader",
          "Small Molecule"
        ],
        "claims": [
          "48 hr Degradation Kinetics",
          "Broad, potent antiproliferative activity in a panel of MM cell lines",
          "CFT7455 is efficacious in MM models resistant or insensitive to IMiDs",
          "CFT7455 promotes regression in tumors insensitive to Pom",
          "CFT7455 retains activity in Len- & Pom-Resistant MM cells",
          "Catalytic activity enhancement resulted in >1000-fold improvement in potency vs. Pom",
          "Class-leading catalytic activity",
          "Deep IKZF3 degradation",
          "Deep IKZF3 degradation and regression in MM xenograft models",
          "Demonstrates high potency in MM cell lines and xenografts",
          "Durable Tumor PK",
          "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
          "Has broad antiproliferative activity",
          "High CRBN binding affinity (KD = 0.9 nM)",
          "High binding affinity",
          "Highly Efficacious",
          "Highly Potent and Selective",
          "Linear, Durable Tumor PK",
          "Pharmacologic profile that enables sustained IKZF1/3 degradation",
          "Promotes durable tumor regression",
          "Rapid, selective, and deep degradation of IKZF1/3 that is associated with apoptosis",
          "Regression in MM xenograft models",
          "Regression in the treatment-na\u00efve H929 MM tumor models at doses \u226510 \u00b5g/kg/day",
          "Selective to reduce off-target liabilities",
          "Single-agent efficacy in models unresponsive to approved IMiDs",
          "fast, selective degradation of IKZF1/3",
          "potent CRBN binder"
        ],
        "safety": [
          "CC-92480 is not detectable after 4 hours",
          "Mouse missing in CFT7455 100 \u00b5g/kg group due to changes unrelated to treatment or disease"
        ]
      },
      "2023": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [
          "small molecule"
        ],
        "claims": [
          "activity in CNS models of lymphoma",
          "demonstrates potent anti-tumor activity",
          "greater efficacy compared to pomalidomide",
          "manageable neutropenia",
          "promising efficacy signals",
          "sCR achieved in a pre-treated MM patient",
          "synergistic activity with rituximab, ibrutinib, and romidepsin",
          "well tolerated"
        ],
        "safety": [
          "manageable neutropenia",
          "well tolerated"
        ]
      },
      "2024": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "MonoDAC\u00ae Degrader"
        ],
        "claims": [
          "Cemsidomide + Dex demonstrated compelling anti-myeloma activity across a broad range of doses",
          "Cemsidomide is a novel, potent, cereblon-based IKZF1/3 MonoDAC\u00ae degrader",
          "Class-leading catalytic activity to enable rapid and deep target degradation",
          "High binding affinity to overcome low cereblon levels that drive resistance to lenalidomide and pomalidomide",
          "Improved pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
        ],
        "safety": [
          "2 DLTs occurred at 100 \u00b5g due to grade 4 thrombocytopenia",
          "38% of patients experienced Grade 3/4 neutropenia, which was manageable",
          "No cases resulted in discontinuation or dose reductions",
          "Only 1 DLT occurred as of the data cutoff date"
        ]
      },
      "2021": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [],
        "claims": [
          "Broad, potent antiproliferative activity in a panel of MM cell lines",
          "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
          "Efficacy in models unresponsive to approved IMiDs",
          "Expected efficacy and survival outcomes when combined with dexamethasone",
          "High CRBN binding affinity (Kd = 0.9 nM)",
          "Rapid, deep degradation of IKZF1/3 that is associated with apoptosis",
          "Regression in multiple treatment-na\u00efve MM tumor models at doses \u226510 \u00b5g/kg/day"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 3
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 11
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 12
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 13
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 14
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 15
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 16
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 17
      },
      {
        "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
        "slide": 20
      },
      {
        "document": "2023_ICML_Poster_CFT-7455_NHL-FINAL_approved (002).pdf",
        "slide": 1
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 10
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 17
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 18
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 10
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 33
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 34
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 36
      },
      {
        "document": "FINAL_CEMSIDOMIDE_POSTER_MM_11.13.24.pdf",
        "slide": 1
      },
      {
        "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
        "slide": 6
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 13
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 3
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "monoDAC",
    "timeline": {
      "2022": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "CRBN"
        ],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 5
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT8919",
    "timeline": {
      "2026": {
        "targets": [
          "EGFR",
          "EGFR C797S",
          "EGFR Exon 21 Mutants",
          "EGFR L858R",
          "EGFR-L861Q"
        ],
        "e3_ligases": [],
        "modalities": [
          "Allosteric Degrader"
        ],
        "claims": [
          "Does not hit wild-type, potentially resulting in better tolerability",
          "Potent and selective against L858R regardless of secondary mutations"
        ],
        "safety": [
          "Toxicities associated with inhibition of wild-type EGFR limit tolerability"
        ]
      },
      "2022": {
        "targets": [
          "EGFR L858R"
        ],
        "e3_ligases": [],
        "modalities": [
          "Oral, Allosteric, Mutant-selective Degrader"
        ],
        "claims": [
          "Active in vitro and in vivo in models with secondary mutations",
          "Demonstrates intracranial activity",
          "May combine with approved EGFR inhibitors",
          "Potential for single agent activity in the front-line setting",
          "Potential to prevent or treat brain metastases"
        ],
        "safety": []
      },
      "2021": {
        "targets": [
          "CCND1",
          "EGFR",
          "EGFR L858R"
        ],
        "e3_ligases": [],
        "modalities": [
          "oral"
        ],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 20
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 21
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 23
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 24
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 25
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 17
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 1
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT8634",
    "timeline": {
      "2022": {
        "targets": [
          "BRD9",
          "{\"dc50\": \"130 nM\", \"emax\": \"30%\", \"name\": \"BRD4\"}",
          "{\"dc50\": \"3 nM\", \"emax\": \"4%\", \"name\": \"BRD9\"}",
          "{\"dc50\": \"5 nM\", \"emax\": \"5%\", \"name\": \"BRD9\"}",
          "{\"dc50\": \">10 \\u00b5M\", \"emax\": \"75%\", \"name\": \"BRD4\"}"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "BiDAC\u2122 degrader",
          "bifunctional degradation activating compound"
        ],
        "claims": [
          "orally bioavailable",
          "potent",
          "selective"
        ],
        "safety": [
          "Frequency and severity of AEs and SAEs of CFT8634"
        ]
      },
      "2023": {
        "targets": [
          "BRD9"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "bifunctional degradation activating compound"
        ],
        "claims": [
          "CFT8634 demonstrated a manageable safety profile",
          "CFT8634 has shown preliminary evidence of anti-tumor activity",
          "CFT8634 is an orally bioavailable selective bifunctional degrader of BRD9"
        ],
        "safety": [
          "Majority of AEs reported were considered mild to moderate in severity",
          "No clear dose dependent relationship to incidence/severity of TEAEs was observed"
        ]
      }
    },
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 10
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 11
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 14
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 15
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 17
      },
      {
        "document": "C4_2206598_CTOS 2022_Final.pdf",
        "slide": 1
      },
      {
        "document": "CFT8634-CTOS 2023 Poster_Final_11.1.23[3].pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT-8634",
    "timeline": {
      "2022": {
        "targets": [
          "BRD9"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 12
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Cemsidomide (CFT7455)",
    "timeline": {
      "2025": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "MonoDAC\u00ae Degrader",
          "MonoDAC\u00ae degrader"
        ],
        "claims": [
          "catalytic activity enabling rapid and deep target degradation",
          "high binding affinity to overcome resistance due to low cereblon levels",
          "pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
        ],
        "safety": [
          "on-target neutropenia"
        ]
      },
      "2024": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [
          "cereblon"
        ],
        "modalities": [
          "MonoDAC\u00ae degrader"
        ],
        "claims": [
          "Catalytic activity enabling rapid and deep target degradation",
          "High binding affinity to overcome resistance due to low cereblon levels",
          "Pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
        ],
        "safety": [
          "On-target neutropenia"
        ]
      }
    },
    "evidence": [
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 1
      },
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 3
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 2
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Cemsidomide 14/14 + Dex",
    "timeline": {
      "2025": {
        "targets": [
          "IKZF1",
          "IKZF3"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-471",
    "timeline": {
      "2022": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "ARV-471 has been well tolerated",
          "Clinical Benefit Rate: 38% (All patients), 51% (Patients with ESR1 mutant tumors)",
          "Continued efficacy and favorable tolerability",
          "Excellent tolerability and signals of efficacy in the most heavily pretreated patients of any ER-targeting therapy",
          "Favorable tolerability at both 200 mg qd and 500 mg qd",
          "Favorable tolerability profile at 200 and 500 mg qd",
          "In 35 patients treated at 200mg (RP3D), no dose reductions and only 1 discontinuation",
          "Mean ER degradation was 71%",
          "Median ER degradation was 69%",
          "No signal for bradycardia or visual disturbance",
          "No single TRAE in more than ~20% of patients",
          "Potential best-in-class estrogen receptor-targeting therapy",
          "Progression-Free Survival: 3.7 Months (All patients), 5.7 Months (Patients with ESR1 mutant tumors)",
          "Strong CBR and mPFS in heavily treatment-resistant patients",
          "best-in-class ER-targeting therapy",
          "demonstrated strong signals of efficacy in the VERITAC Phase 2 trial",
          "validated PROTAC protein degrader"
        ],
        "safety": [
          "ALT increased (n=1)",
          "Back pain/spinal cord compression (n=1)",
          "ECG T-wave abnormality (n=1)",
          "Fatigue (n=1)",
          "Grade 3/4 TRAE reported in 6% (2/35) patients at 200 mg",
          "In 35 patients treated at the recommended Phase 3 dose (200 mg), no dose reduction and 1 discontinuation",
          "Neutropenia (n=1)",
          "No dose reductions and one discontinuation at 200 mg phase 3 dose",
          "QT prolongation (n=1)",
          "favorable safety profile",
          "favorable tolerability profile"
        ]
      },
      "2020": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "80% of breast cancers are estrogen receptor (ER) positive",
          "Achieved significant tumor shrinkage in combination with palbociclib (131% TGI) in an MCF-7 xenograft mouse model",
          "Compelling efficacy signal in heavily pretreated patients",
          "Fulvestrant has demonstrated the value of ER degradation in breast cancer",
          "In all 10 mice in experiment, tumors reduced by >80%",
          "In corresponding quantitative western blots, ER is reduced by 79% and 88% in the 10 mpk and 30 mpk arms, respectively, vs. 63% for fulvestrant",
          "Oral, daily dose of ARV-471 inhibited tumor growth by 99% at 10 mpk and 106% at 30 mpk in an ESR1 mutant PDX model",
          "Superior ER degradation compared to SERDs",
          "Superior inhibitor of tumor growth compared to fulvestrant",
          "Superior tumor growth inhibition versus fulvestrant in a Y537S (ER gene mutation) PDX model",
          "Superior tumor shrinkage (in combination with palbociclib) compared to fulvestrant (108% TGI)",
          "Well tolerated, with manageable adverse events",
          "dose-proportional pharmacokinetics",
          "early evidence of ER degradation",
          "fast-to-market strategy",
          "no DLTs; dose escalation continues",
          "potential first- and best-in-class ER degrader",
          "superior ER degradation and tumor inhibition in preclinical studies"
        ],
        "safety": [
          "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety",
          "No treatment-related AEs or DLTs were observed in the first cohort of ARV-471",
          "Well tolerated, with manageable adverse events",
          "no DLTs"
        ]
      },
      "2025": {
        "targets": [
          "estrogen receptor"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [],
        "safety": [
          "Its safety and effectiveness have not been established."
        ]
      },
      "2021": {
        "targets": [
          "ER",
          "Target 1",
          "Target 2"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC",
          "oral, high-potency ER degrader"
        ],
        "claims": [
          "68% Reduction in ER after treatment with 60 mg ARV-471",
          "89% of TRAEs were grade 1/2 in severity with no DLTs",
          "Begin early breast cancer study (neoadjuvant setting)",
          "Confirmed RECIST Partial Response in a patient with extensive prior therapy and an ESR1 mutation at 120 mg",
          "First-in-class ER-degrading PROTAC",
          "Initiate Phase 1b combination study with everolimus",
          "Share completed Phase 1 data",
          "average degradation of 62%",
          "clinical benefit rate (CBR) of 40%",
          "confirmed partial responses",
          "degraded ER up to 90% through the 120 mg dose level",
          "early clinical benefit",
          "maximum ER degradation of 89%",
          "oral, best-in-class ER-directed therapy",
          "potential to degrade ER better than fulvestrant",
          "robust signals of efficacy"
        ],
        "safety": [
          "favorable safety profile"
        ]
      },
      "2024": {
        "targets": [
          "LRRK2"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 7
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 9
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 1
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 10
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 59
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 9
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 10
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 11
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 12
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 13
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 20
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 13
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 13
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 14
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 15
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 16
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 17
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 33
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 1
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 13
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 14
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 1
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 2
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 4
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 5
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 6
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 7
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 8
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 13
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 14
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 16
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 17
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 19
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 20
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 4
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 11
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "bavdegalutamide",
    "timeline": {
      "2022": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "0% Grade \u22654 TRAEs",
          "2 of 7 RECIST-evaluable patients with durable partial responses",
          "43% of patients remained on treatment for 24 weeks or more",
          "46% PSA50 rate",
          "46% PSA50 response rate in patients with AR T878X/H875Y-positive tumors",
          "6 of 7 patients with tumor reductions",
          "Low rates of discontinuation and dose reduction",
          "potential path to accelerated approval",
          "unmet need expected to increase as NHAs move earlier"
        ],
        "safety": [
          "Manageable tolerability profile",
          "manageable tolerability"
        ]
      },
      "2020": {
        "targets": [
          "androgen receptor"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "degrades wild-type AR and clinically relevant mutants",
          "first-in-class",
          "promising efficacy profile"
        ],
        "safety": [
          "76% of patients received prior chemotherapy",
          "82% received both abiraterone and enzalutamide",
          "84% had non-AR gene mutations",
          "heavily pretreated patient population"
        ]
      }
    },
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 12
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 13
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 5
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 21
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 22
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "BCL-057",
    "timeline": {
      "2023": {
        "targets": [
          "BCL6"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "Complete tumor stasis at low, oral daily doses",
          "Tumor stasis correlates with 95-100% degradation of measurable BCL6",
          "inhibits tumor growth by nearly 100%"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 16
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "vepdegestrant",
    "timeline": {
      "2025": {
        "targets": [
          "ESR1"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "2.9-month improvement over fulvestrant",
          "5-month median PFS",
          "BEST-IN-CLASS TREATMENT without tradeoffs between efficacy, tolerability, and patient reported outcomes",
          "best-in-class treatment",
          "clinically meaningful median PFS benefit over fulvestrant",
          "first-in-class oral PROTAC estrogen receptor degrader",
          "potential best-in-class profile"
        ],
        "safety": [
          "Favorable safety/tolerability profile",
          "Low rate of discontinuation (2.9%)",
          "Low rates and severity of GI-related events",
          "safety and tolerability provide further evidence",
          "{\"Any Grade\": 11, \"Grade 3/4\": 0, \"TEAE\": \"Arthralgia\"}",
          "{\"Any Grade\": 11, \"Grade 3/4\": 0, \"TEAE\": \"Back pain\"}",
          "{\"Any Grade\": 11, \"Grade 3/4\": 0, \"TEAE\": \"Decreased appetite\"}",
          "{\"Any Grade\": 11, \"Grade 3/4\": 1, \"TEAE\": \"Neutropenia\"}",
          "{\"Any Grade\": 12, \"Grade 3/4\": 0, \"TEAE\": \"Nausea\"}",
          "{\"Any Grade\": 12, \"Grade 3/4\": 1, \"TEAE\": \"Anemia\"}",
          "{\"Any Grade\": 13, \"Grade 3/4\": 1, \"TEAE\": \"AST increased\"}",
          "{\"Any Grade\": 14, \"Grade 3/4\": 1, \"TEAE\": \"ALT increased\"}",
          "{\"Any Grade\": 27, \"Grade 3/4\": 14, \"TEAE\": \"Fatigue\"}"
        ]
      }
    },
    "evidence": [
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 6
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 15
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 10
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 62
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 63
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 70
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 71
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "Vepdegestrant",
    "timeline": {
      "2025": {
        "targets": [
          "ESR1"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "2.5x improvement in mPFS over SoC",
          "best-in-class treatment without tradeoffs between efficacy, tolerability, and patient reported outcomes",
          "clinically meaningful median PFS benefit over fulvestrant",
          "demonstrate clinical benefit",
          "favorable safety/tolerability",
          "improvement in mPFS (5.0m vs. 2.1m) vs. fulvestrant",
          "low rates and severity of GI-related events",
          "met the primary endpoint with a ~3-month improvement in mPFS in patients with tumors harboring ESR1 mutations",
          "potential best-in-class profile",
          "significantly reduced risk of clinically meaningful definitive deterioration in measures of overall health status compared to fulvestrant",
          "statistically significant improvements in CBR and ORR in the ESR1 mutant population"
        ],
        "safety": [
          "favorable safety/tolerability",
          "low rates and severity of GI-related events",
          "safety and tolerability provide further evidence",
          "{\"Fulvestrant\": 0, \"TEAE\": \"Leading to dose reduction\", \"Vepdegestrant\": 2}",
          "{\"Fulvestrant\": 1, \"TEAE\": \"Arthralgia\", \"Vepdegestrant\": 1}",
          "{\"Fulvestrant\": 1, \"TEAE\": \"Leading to treatment discontinuation\", \"Vepdegestrant\": 3}",
          "{\"Fulvestrant\": 1, \"TEAE\": \"QT prolongation\", \"Vepdegestrant\": 10}",
          "{\"Fulvestrant\": 10, \"TEAE\": \"ALT increased\", \"Vepdegestrant\": 14}",
          "{\"Fulvestrant\": 10, \"TEAE\": \"AST increased\", \"Vepdegestrant\": 12}",
          "{\"Fulvestrant\": 16, \"TEAE\": \"Fatigue\", \"Vepdegestrant\": 27}",
          "{\"Fulvestrant\": 18, \"TEAE\": \"Grade \\u22653\", \"Vepdegestrant\": 23}",
          "{\"Fulvestrant\": 5, \"TEAE\": \"Decreased appetite\", \"Vepdegestrant\": 1}",
          "{\"Fulvestrant\": 5, \"TEAE\": \"Neutropenia\", \"Vepdegestrant\": 11}",
          "{\"Fulvestrant\": 7, \"TEAE\": \"Back pain\", \"Vepdegestrant\": 11}",
          "{\"Fulvestrant\": 8, \"TEAE\": \"Anemia\", \"Vepdegestrant\": 11}",
          "{\"Fulvestrant\": 81, \"TEAE\": \"Any grade\", \"Vepdegestrant\": 87}",
          "{\"Fulvestrant\": 9, \"TEAE\": \"Nausea\", \"Vepdegestrant\": 12}",
          "{\"Fulvestrant\": 9, \"TEAE\": \"Serious\", \"Vepdegestrant\": 10}"
        ]
      }
    },
    "evidence": [
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 8
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 11
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 12
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 13
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 14
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 17
      },
      {
        "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
        "slide": 18
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 66
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 67
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 68
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-110",
    "timeline": {
      "2020": {
        "targets": [
          "AR",
          "Androgen Receptor",
          "F877L",
          "H875Y",
          "M895V",
          "T878A",
          "androgen receptor"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "10 mpk ARV-110: 70% tumor growth inhibition",
          "ARV-110 demonstrates efficacy and plasma PSA reduction in an enzalutamide-insensitive patient derived xenograft model",
          "ARV-110 inhibits tumor growth in an in vivo model of acquired enzalutamide resistance",
          "Anti-Tumor Activity (PSA, RECIST)",
          "Biomarkers",
          "Confirmed RECIST partial response in a patient with a PCWG3",
          "Daily and orally delivered ARV-110 significantly inhibited tumor growth",
          "Degrades >90% AR protein in vivo",
          "Duration of ARV\u2010110: 18 weeks and ongoing",
          "In vivo activity in multiple xenograft models",
          "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety",
          "Near complete regression of adenopathy after 4 cycles",
          "Orally delivered ARV-110 significantly inhibited tumor growth in these intrinsically enza-insensitive tumors (TGI: 100%)",
          "PSA: 97% decline",
          "Pharmacokinetics",
          "Plasma PSA levels following ARV-110 treatment significantly decreased vs. mice treated with vehicle or enzalutamide",
          "Preclinical profile translating into clinical benefit",
          "Proves the concept of PROTAC targeted protein degradation, validating our confidence in our pipeline of degraders",
          "Proving the concept of PROTAC protein degradation",
          "RECIST: 80% reduction in tumor measurements",
          "Signals of efficacy in a heavily pretreated patient population with high unmet need, where traditional inhibitors have failed",
          "clear initial efficacy signal in dose escalation",
          "degrades AR in tumor tissue",
          "early clinical proof-of-concept (safety, AR degradation, efficacy) demonstrated",
          "first PROTAC degrader with an efficacy signal in humans",
          "first evidence for androgen receptor degradation in patients",
          "first proof of mechanism for PROTAC\u00ae protein degraders",
          "highly selective degradation of AR",
          "overcomes known resistance mechanisms to enzalutamide and abiraterone",
          "overcomes mechanisms of resistance to current standards of care",
          "potential to address unmet patient need in 1L mCRPC and mCSPC",
          "potentially first- and best-in-class AR-targeted therapy",
          "safety profile acceptable for potential use in frontline settings",
          "selectively degrades AR"
        ],
        "safety": [
          "6 patients on other statins, including 3 on atorvastatin (Lipitor\u00ae) and no ALT/AST adverse events",
          "ARV-110 is not blood-brain barrier penetrant",
          "Does not degrade L702H or AR-V7",
          "Dose increases dependent on toxicities: range 25% (if 1 DLT in 6 pts) to 100% (\u2264Grade 1 Adverse Events)",
          "First patient with DLT: Grade 3/4 ALT/AST and renal failure",
          "Following introduction of rosuvastatin restriction, no further elevation in LFTs observed",
          "No DLTs",
          "No dose limiting toxicities (DLTs)",
          "No grade 2/3/4 treatment related AEs",
          "No treatment related Adverse Events (AEs)",
          "Patient continues on ARV\u2010110 with no further toxicity",
          "Second patient with Grade 3 ALT/AST; re\u2010challenge off rosuvastatin supported contribution of rosuvastatin",
          "dose escalation continues",
          "early clinical safety data presented",
          "favorable safety profile observed in the first 3 cohorts",
          "generally well tolerated",
          "initial safety/pharmacokinetic data shared Oct. 2019",
          "{\"adverse_event\": \"ALT increased\", \"count\": 5, \"grade\": \"Gr \\u22642\", \"percentage\": 23}",
          "{\"adverse_event\": \"AST increased\", \"count\": 4, \"grade\": \"Gr \\u22642\", \"percentage\": 18}",
          "{\"adverse_event\": \"Diarrhea\", \"count\": 6, \"grade\": \"Gr \\u22642\", \"percentage\": 27}",
          "{\"adverse_event\": \"Fatigue\", \"count\": 6, \"grade\": \"Gr \\u22642\", \"percentage\": 27}",
          "{\"adverse_event\": \"Lymphocyte count decreased\", \"count\": 4, \"grade\": \"Gr \\u22642\", \"percentage\": 18}",
          "{\"adverse_event\": \"Nausea\", \"count\": 13, \"grade\": \"Gr \\u22642\", \"percentage\": 59}",
          "{\"adverse_event\": \"Vomiting\", \"count\": 4, \"grade\": \"Gr \\u22642\", \"percentage\": 18}"
        ]
      },
      "2022": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "Robust signals of efficacy",
          "manageable tolerability",
          "potential path to accelerated approval"
        ],
        "safety": [
          "Low rates of discontinuation or dose reduction from the RP2D due to TRAEs",
          "The majority of TRAEs are Grade 1 or 2",
          "no Grade \u22654 TRAEs"
        ]
      },
      "2021": {
        "targets": [
          "androgen receptor"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "AR degradation and late-line activity suggest strong potential across multiple disease states",
          "AR molecular profiling identifies a molecularly defined, late line population that may offer a possible path to accelerated approval",
          "ARV-110 has shown clinical benefit in Phase 1 in a highly refractory patient population",
          "ARV-110 is well tolerated, allowing continued dose escalation up to 700 mg daily",
          "encouraging efficacy signals",
          "may overcome point mutations and other drivers of resistance",
          "substantially exceeded expectations for PSA50 responses",
          "suggests potential for accelerated approval",
          "suggests potential in early prostate cancer"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 1
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 3
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 4
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 6
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 8
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 9
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 11
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 12
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 14
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 15
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 16
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 17
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 19
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 20
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 21
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 22
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 26
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 1
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 3
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 14
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 15
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 16
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 17
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 11
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 12
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 1
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 8
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 9
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 10
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 11
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 12
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 31
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 32
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARDENT",
    "timeline": {
      "2021": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "High potential for patient benefit in earlier-line, more AR-dependent patients",
          "Strong signal in molecularly defined patient populations",
          "Well tolerated; no TRAEs Gr >2"
        ],
        "safety": [
          "Safety cut-off date: October 2, 2020"
        ]
      }
    },
    "evidence": [
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 35
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "AR T878X/875Y",
    "timeline": {
      "2022": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "46% PSA50 rate",
          "Durable partial responses",
          "Tumor regression"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-102",
    "timeline": {
      "2025": {
        "targets": [
          "C1QTNF1",
          "CD68",
          "CTSH",
          "Cathepsin B",
          "ENTPD1",
          "GPNMB",
          "GRN",
          "IBA1",
          "LRRK2",
          "TMEM106A"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "50x greater pathway engagement with ARV-102",
          "50x greater target engagement with ARV-102",
          ">50% decreases in phospho-Rab10T73 and BMP in urine",
          "ARV-102 degrades LRRK2 in NHP deep-brain regions",
          "ARV-102 induced dose-dependent reductions in LRRK2 levels in CSF, with >50% LRRK2 reduction at single doses \u226560 mg and repeated doses \u226520 mg",
          "CSF levels of LRRK2 track cortex LRRK2",
          "Cathepsin B is reduced by ARV-102",
          "Decreased LRRK2 protein levels in PBMCs after a single oral dose",
          "Dose-dependently increased degradation efficiency and lysosome number vs kinase inhibitors",
          "Enrollment complete",
          "Final data from HV SAD/MAD cohorts presented at MDS",
          "First-in-human data presented during oral presentation at AD/PD",
          "GPNMB is reduced by ARV-102",
          "IBA1 is reduced by ARV-102",
          "Increases lysosome degradation in A549 cells",
          "Increases lysosome functional degradative capacity and number in cells",
          "Increases lysosome number in A549 cells",
          "Investigational compound. Its safety and effectiveness have not been established.",
          "Orally dosed ARV-102 reaches multiple deep brain regions in NHPs and degrades LRRK2 up to 94%",
          "Presenting initial single ascending dose data",
          "Putative LRRK2 biomarkers associated with disease are reduced in non-human primate CSF after dosing with ARV-102",
          "better target engagement",
          "dose-dependent increases in LRRK2 reductions in CSF indicate brain penetration and target engagement",
          "dose-dependent increases in exposure in cerebral spinal fluid after single and multiple doses indicated brain penetration",
          "enhanced potency",
          "normalization of cytokine and purinergic signaling",
          "pathway engagement versus a LRRK2 inhibitor",
          "reduced lysosomal markers reflecting effects on proteolysis, lysosomal integrity, and microglial activation",
          "reductions in downstream LRRK2 pathway biomarkers in blood cells and urine",
          "significant reductions in lysosomal pathway markers"
        ],
        "safety": [
          "Safety",
          "Tolerability"
        ]
      },
      "2024": {
        "targets": [
          "LRRK2"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC",
          "PROTAC\u00ae Degrader"
        ],
        "claims": [
          "Potential for oral therapies",
          "Potential to cross the blood brain barrier and degrade disease-causing proteins inside cells",
          "Specifically target pathogenic proteins in the brain"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 11
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 13
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 17
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 19
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 20
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 22
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 23
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 24
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 25
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 26
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 27
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 28
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 1
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 5
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 14
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-027",
    "timeline": {
      "2025": {
        "targets": [
          "polyQ-AR"
        ],
        "e3_ligases": [
          "True"
        ],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "induced polyQ-AR degradation in muscle tissues",
          "rescued strength and endurance"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 29
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 32
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 33
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-393",
    "timeline": {
      "2025": {
        "targets": [
          "BCL6",
          "CDKN1B",
          "IRF4",
          "PTPN6"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "ARV-393 rapidly degrades >90% of BCL6 within 2 hours",
          "Broad combinability with complete tumor regressions in combination with SOC biologics and investigational small molecule agents",
          "Demonstrated significant anti-tumor single-agent activity",
          "Potent, orally bioavailable PROTAC small molecule degrader of BCL6",
          "breadth of efficacy beyond DLBCL demonstrated in multiple patient-derived xenograft (PDX) models with no body weight loss",
          "degradation is mediated by PROTAC mechanism",
          "demonstrated >90% TGI",
          "demonstrates activity in combination with SOC chemotherapy/biologics",
          "demonstrates activity in combination with small molecule inhibitors",
          "drives tumor regressions, including complete responses",
          "drives tumor regressions, including complete responses, in preclinical models",
          "evidence of significant efficacy comparable to SOC romidepsin",
          "exhibits picomolar degradation potency",
          "induces dose-dependent and sustained tumor growth inhibition",
          "induces tumor growth inhibition in PDX models of various non-Hodgkin lymphoma subtypes",
          "investigational compound",
          "no adverse impact on animal health/body weight",
          "overcomes BCL6 high resynthesis rate",
          "potential to be an attractive combination partner for development of novel treatment options",
          "potently degrades BCL6",
          "safety and effectiveness have not been established",
          "tumor regression at 30 mg/kg dosed once per day"
        ],
        "safety": [
          "no body weight loss"
        ]
      }
    },
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 34
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 37
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 38
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 39
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 40
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 41
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 42
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 43
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 44
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 45
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 46
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 47
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-806",
    "timeline": {
      "2025": {
        "targets": [
          "KRAS G12D"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          ">25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS G12D ON and OFF inhibitors and a clinical-stage G12D degrader",
          ">25-fold more potent than all G12D-targeting competitors",
          ">40-fold higher potency in degrading KRAS G12D protein vs the comparable clinical-stage G12D degrader",
          ">40-fold more potent than KRAS G12D levels",
          "ARV-806 degrades KRAS G12D with picomolar potency",
          "ARV-806 demonstrates exquisite selectivity for KRAS G12D, indicating a robust therapeutic index",
          "ARV-806 effectively eliminates KRAS G12D from cancer cells",
          "ARV-806 forms a ternary complex with both OFF (GDP-bound) and ON (GTP-bound) KRAS G12D",
          "ARV-806 is a highly potent, selective degrader of KRAS G12D",
          "ARV-806 is selective for KRAS G12D",
          "ARV-806 treatment directly leads to ubiquitination of KRAS G12D protein",
          "Catalytic activity (overcomes upregulation, a common mechanism of resistance to inhibitor treatment)",
          "Demonstrates anti-proliferative activity approximately 25 times greater than KRAS inhibitors and the leading clinical-stage degrader",
          "Investigational compound. Safety and effectiveness have not been established.",
          "KRAS G12D reduced >90% for 7 days",
          "Proliferative marker (c-MYC) suppressed and pro-apoptotic marker (BIM) increased for 5 days",
          "Targeting both OFF and ON KRAS G12D allows ARV-806 to eliminate this oncogenic protein from the cell",
          "leads to robust and extended degradation and signaling suppression in vivo",
          "more potently increases apoptosis (cell death)",
          "more potently induces pancreatic cancer cell death in vitro relative to clinical-stage inhibitors and degrader",
          "\u226530% tumor volume reductions in a patient-derived xenograft (PDX) model of lung cancer",
          "\u226530% tumor volume reductions in pancreatic and colorectal CDX models"
        ],
        "safety": [
          "pharmacokinetics (PK)",
          "preliminary antitumor activity",
          "safety",
          "tolerability"
        ]
      }
    },
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 48
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 49
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 52
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 53
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 54
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 55
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 56
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 57
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 58
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "VEPDEGESTRANT",
    "timeline": {
      "2025": {
        "targets": [
          "estrogen receptor"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "Patient reported outcomes data demonstrate that vepdegestrant significantly reduced risk of deterioration in measures of overall health status compared to fulvestrant",
          "Vepdegestrant met its primary endpoint of improvement in progression-free survival versus the standard of care, fulvestrant",
          "Vepdegestrant was well tolerated, with low rates of discontinuation"
        ],
        "safety": [
          "low rates of discontinuation",
          "well tolerated"
        ]
      }
    },
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 61
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-766",
    "timeline": {
      "2023": {
        "targets": [
          "AR L702H",
          "H875Y",
          "T878X"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "3 of 3 patients with co-occurring AR T878/H875/L702H mutations achieved PSA50",
          "42% of patients with AR LBD mutations achieved PSA50",
          "RECIST partial responses observed",
          "addresses an unmet need for durable and tolerable treatments",
          "good tolerability profile",
          "low rates of discontinuation or dose reduction",
          "majority of TRAEs are Grade 1 or 2",
          "no Grade \u22654 TRAEs",
          "precision medicine opportunity",
          "promising efficacy signals",
          "promising efficacy signals in heavily pretreated patients",
          "promising efficacy signals in late-line mCRPC",
          "well-tolerated"
        ],
        "safety": [
          "low rates of discontinuation or dose reduction",
          "majority of TRAEs are Grade 1 or 2",
          "no Grade \u22654 TRAEs",
          "well tolerated to date",
          "{\"AST_increased\": 0, \"Cr_increased\": 1, \"diarrhea\": 1, \"dry_mouth\": 0, \"fatigue\": 3, \"grade\": 2, \"hypophosphataemia\": 0, \"nausea\": 2, \"total\": 7}",
          "{\"AST_increased\": 1, \"Cr_increased\": 0, \"fatigue\": 1, \"grade\": 3, \"total\": 2}",
          "{\"AST_increased\": 2, \"Cr_increased\": 2, \"diarrhea\": 3, \"dry_mouth\": 2, \"fatigue\": 3, \"grade\": 1, \"hypophosphataemia\": 2, \"nausea\": 2, \"total\": 9, \"vomiting\": 2}"
        ]
      }
    },
    "evidence": [
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 3
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 4
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 5
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 7
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 9
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "BCL6",
    "timeline": {
      "2020": {
        "targets": [
          "BCL6"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          ">95% degradation of BCL6 in vivo"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 18
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "Tg25081",
    "timeline": {
      "2020": {
        "targets": [
          "tau"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "Dose-Dependently Reduce tau in the Brain of Tauopathy Mice Following Parenteral Administration"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 20
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "PROTAC 1",
    "timeline": {
      "2020": {
        "targets": [
          "p38\u03b1"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 30
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "LRRK2 PROTAC",
    "timeline": {
      "2024": {
        "targets": [
          "LRRK2"
        ],
        "e3_ligases": [],
        "modalities": [
          "PROTAC"
        ],
        "claims": [
          "LRRK2 PROTAC degraders induce reduction of pathologic tau",
          "Reduction of pathologic (AT8) Tau induced by LRRK2 PROTAC",
          "enhances lysosome-based degradation",
          "induces enhanced lysosomal clearance"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 8
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 9
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "bexobrutideg",
    "timeline": {
      "2026": {
        "targets": [
          "BTK"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "22.1-month median PFS",
          "83% ORR",
          "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
          "Acts catalytically with unprecedented potency",
          "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
          "Degradation removes all functions of BTK unlike BTK inhibitors",
          "Demonstrates robust clinical activity in difficult to treat B-cell malignancies",
          "Exquisitely selective degrader of BTK",
          "Long-term Disease Control",
          "No dose-limiting toxicities",
          "No systemic fungal infections or Grade 4 infections of any kind reported",
          "Robust Response Rate",
          "Tolerable safety profile"
        ],
        "safety": [
          "Comparable AE profile for patients overall and at the 600 mg dose selected per Project Optimus",
          "Single event of new onset atrial fibrillation consistent with the rate in the age-matched general population",
          "Three Grade 5 AEs (all deemed not related to bexobrutideg)"
        ]
      },
      "2025": {
        "targets": [
          "BTK"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader",
          "small molecule"
        ],
        "claims": [
          "130 NHL patients treated to date in NX-5948-301",
          "75% ORR in WM with responses deepening over time including 3 VGPRs",
          "83% ORR with a 20.1 month median duration of response in CLL",
          "Accelerated Approval",
          "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
          "Acts catalytically driving degradation at low free-plasma concentrations",
          "Addresses BTK scaffolding function unlike current BTK inhibitors",
          "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
          "Demonstrates robust clinical activity in difficult to treat B-cell malignancies",
          "Median duration of response was not reached in WM",
          "Multiple CR/CMRs observed in all cohorts (DLBCL, MCL, FL, MZL, PCNSL)",
          "ORR of 83.0%",
          "Potent and exquisitely selective degrader of BTK",
          "Progression free survival tracking well above standard of care with a current estimate of 22.1 months in CLL",
          "Well tolerated with low rate of discontinuation in CLL",
          "can overcome treatment-emergent BTKi resistance mutations",
          "disrupt BTK scaffolding",
          "maximizes 2L market share opportunity",
          "median DOR of 20.1 months",
          "median PFS of 22.1 months",
          "provides potential path to 1L CLL",
          "will outperform all components of the investigator\u2019s choice arm"
        ],
        "safety": [
          "AEs predominantly low grade",
          "No DLTs noted",
          "No atrial fibrillation observed",
          "Safety Run-in",
          "Well tolerated with low rate of discontinuation in CLL",
          "most common AEs were neutropenia, petechiae, diarrhea, anemia, purpura/contusion, and thrombocytopenia",
          "no Grade 5 AEs",
          "safety follow-up",
          "two TEAEs led to drug discontinuation",
          "well tolerated"
        ]
      }
    },
    "evidence": [
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 5
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 8
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 14
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 15
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 7
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 10
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 35
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 37
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 38
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 40
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 41
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 42
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 45
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "Bexobrutideg",
    "timeline": {
      "2026": {
        "targets": [
          "BTK"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "Accelerated Approval",
          "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
          "Acts catalytically with unprecedented potency",
          "Crosses the blood brain barrier with clinical responses",
          "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
          "Degradation removes all functions of BTK",
          "Degradation removes all functions of BTK unlike BTK inhibitors",
          "Demonstrates robust clinical activity in difficult to treat B-cell malignancies",
          "Designed to evaluate superiority to latest approved BTKi, pirtobrutinib",
          "Efficacy across all doses (50mg \u2013 600mg)",
          "Exquisitely selective degrader of BTK",
          "First 'deg' with a potential best-in-class profile",
          "High objective response rate",
          "Median progression-free survival (PFS) 22.1 months",
          "Most potent cell killing",
          "Objective response rate (ORR) 83.0%",
          "Only BTK degrader to demonstrate clinical activity in patients with CNS disease including complete responses",
          "Prolonged PFS",
          "Removes both BTK enzymatic activity and scaffolding functions",
          "Selectively degrades BTK with no off-target degradation",
          "Superior mutational coverage compared to BTK inhibitors"
        ],
        "safety": [
          "Safety follow-up"
        ]
      },
      "2025": {
        "targets": [
          "BTK"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
          "Acts catalytically driving degradation at low free-plasma concentrations",
          "Addresses BTK scaffolding function unlike current BTK inhibitors",
          "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
          "Demonstrates robust clinical activity in difficult to treat B-cell malignancies",
          "High Overall Response Rate",
          "High objective response rate and prolonged PFS in r/r CLL patients",
          "Median progression-free survival (PFS) 22.1 months",
          "Objective response rate (ORR) 83.0%",
          "Potent and exquisitely selective degrader of BTK",
          "Potential to address a current and anticipated future unmet medical need"
        ],
        "safety": [
          "600 mg cleared for pivotal studies in r/r CLL"
        ]
      }
    },
    "evidence": [
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 7
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 9
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 10
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 11
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 12
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 18
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 19
      },
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 22
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 1
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 4
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 5
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 6
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 8
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 9
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 15
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 30
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 33
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 36
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 39
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948-203",
    "timeline": {
      "2026": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "ORR per iwCLL as assessed by IRC"
        ],
        "safety": [
          "Safety follow-up",
          "Safety run-in"
        ]
      }
    },
    "evidence": [
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 20
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "Bexobrutideg (NX-5948)",
    "timeline": {
      "2025": {
        "targets": [
          "Bruton\u2019s Tyrosine Kinase (BTK)",
          "Bruton\u2019s tyrosine kinase (BTK)"
        ],
        "e3_ligases": [],
        "modalities": [
          "Degrader",
          "degrader"
        ],
        "claims": [
          "Demonstrates Rapid and Durable Clinical Responses",
          "High Clinical Activity",
          "Shows High Clinical Activity and Tolerable Safety",
          "Tolerable Safety",
          "demonstrates rapid and durable clinical responses"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 12
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 14
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 29
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948",
    "timeline": {
      "2025": {
        "targets": [
          "Bruton\u2019s Tyrosine Kinase (BTK)"
        ],
        "e3_ligases": [],
        "modalities": [
          "degrader"
        ],
        "claims": [
          "Demonstrates Rapid and Durable Clinical Responses",
          "Shows High Clinical Activity and Tolerable Safety"
        ],
        "safety": []
      }
    },
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 13
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 28
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948-301",
    "timeline": {
      "2025": {
        "targets": [],
        "e3_ligases": [],
        "modalities": [],
        "claims": [],
        "safety": [
          "{\"discontinued_treatment\": 13, \"reasons\": {\"adverse_event\": 4, \"clinical_progression\": 5, \"death\": 1, \"physician_decision\": 1, \"radiographic_progression\": 2}}",
          "{\"discontinued_treatment\": 22, \"reasons\": {\"adverse_event\": 4, \"clinical_progression\": 5, \"death\": 1, \"patient_withdrew_consent\": 1, \"physician_decision\": 1, \"prohibited_medication_procedure\": 1, \"radiographic_progression\": 9}}"
        ]
      }
    },
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 16
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 17
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "bexobrutideg (NX-5948)",
    "timeline": {
      "2025": {
        "targets": [
          "BTK"
        ],
        "e3_ligases": [],
        "modalities": [],
        "claims": [
          "CR rate of 4.3%",
          "Median DOR of 20.1 months",
          "Median PFS of 22.1 months",
          "ORR of 83%",
          "higher ORR and superior PFS at the 600 mg dose",
          "well tolerated in a heavily pretreated population"
        ],
        "safety": [
          "tolerable safety profile consistent with prior disclosures"
        ]
      }
    },
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 27
      }
    ]
  }
]